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another 3.6 million are at an increased risk. In men over 64 years
of age, 80% of hip fractures are attributed to osteoporosis,
costing a national direct expenditure of $13.8 billion in 2000.
Earliest diagnosis is through a bone density test, which could
help in prevention of hip fractures and signiﬁcant savings in
health care costs. This study examines the various physician and
patient factors, which inﬂuence the bone density test prescribing
for osteoporosis in male ambulatory patients. METHODS:
Patient factors such as age, race, geographical location and
payment source, and Physician factors such as specialty and
referral status were used to determine their inﬂuence on the
number of bone density tests prescribed. Data from the National
Ambulatory Medical Care Survey (NAMCS) 2002 were utilized.
Male patients with principal diagnosis of osteoporosis (ICD-9-
CM code 733.00) with age more than or equal to 50 years were
analyzed using multiple linear and binomial logit regression
models. RESULTS: The number of bone density tests performed
were independent of patients’ geographic region (R2 = 0.111).
White patients were prescribed more bone density tests com-
pared to other races (R2 = 0.436). Patients above 75 years of age
and patients with Federal source of payments were prescribed
more bone density tests than other patients (R2 = 0.345).
Numbers of bone density tests were not inﬂuenced by whether
the patient was referred (R2 = 0.027). Family Practice physicians
prescribed more bone density tests compared to other specialties
(R2 = 0.326). CONCLUSIONS: The numbers of bone density
tests prescribed are signiﬁcantly inﬂuenced by patients’ race, age
and source of payments, and physician’s specialty. Bone density
screening for men over 50 years of age appears to be an optimal
approach to manage osteoporosis in men.
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OBJECTIVES: A preexisting fracture is a very strong predictor
of subsequent osteoporotic fractures, emphasizing the need to
aggressively treat patients with existing osteoporotic fractures.
The objectives of the study are to examine the prevalence of drug
treatment and factors associated with drug treatment among
elderly nursing home (NH) admissions with an indication of
osteoporotic fracture. METHODS: The Minimum Data Set for
Nursing Home Assessment and Care Screening (MDS) Version
2.0 and physicians’ medication orders from 1999 were utilized
for this study. The outcome was the use of anti-osteoporotic drug
therapy at NH admission. Independent variables included
patient demographics, comorbidities, functional capabilities
(activities of daily living or ADLs), and cognitive performance
(MDS-COGS). Multivariate analysis was conducted using logis-
tic regression with Generalized Estimating Equations (GEE) to
adjust for clustering within NH facilities. RESULTS: A total of
2673 NH residents were identiﬁed with documentation of osteo-
porotic fracture within 180 days or affecting current care at
admission; however, only 642 (24.02%) received anti-osteo-
porotic drug therapy at admission. Gender (p < 0.0001), age (p
= 0.0394), and functional capabilities (p = 0.0002) were signiﬁ-
cantly associated with the use of anti-osteoporotic drug. Non-
signiﬁcant factors were region, race, education, comorbidity and
cognition. Treatment was less likely for male residents (OR:
0.45; 95% CI, 0.33–0.62) and residents older than 85 (OR: 0.79;
95% CI, 0.67–0.97). Those who were independent in terms of
ADLs were more likely to receive drug treatment (OR: 2.54;
95% CI, 1.27–5.07), compared to those who were fully depen-
dent. CONCLUSIONS: While osteoporotic fracture is common
among the NH elderly population, the majority remained
untreated. Increasing age was inversely related to receipt of anti-
osteoporotic drugs. Female elderly and those with fewer limita-
tions in daily activities were more likely to receive drug therapy
for osteoporosis.
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OBJECTIVE: To evaluate the impact of an osteoporosis therapy
intervention program in a health plan setting. METHODS: A
clinical team of pharmacists, obstetricians/gynecologists and
endocrinologists designed and implemented an educational ini-
tiative for physicians and members. Medical and pharmacy
claims data for female enrollees over the age of 40 were retrieved
for the time period of July, 2002 through June, 2003. Criteria
for targeted patients included a fracture history (deﬁned by ICD-
9 and CPT codes) and negative history of estrogen/progestin use
over the 1-year period, and four-month negative history of osteo-
porosis therapy (alendronate, risedronate, calcitonin, raloxifene,
or teriparatide). Physicians received a patient list, an educational
tool for management of osteoporosis and coupons for a free ﬁrst-
month supply of a bisphosphonate. Targeted members received
a 17-page handbook highlighting drug treatment, lifestyle mod-
iﬁcations, and information regarding prescription drug discount
programs. The impact of the intervention was analyzed using
pharmacy claims data for eligible patients with pharmacy bene-
ﬁts. Primary outcome measure was deﬁned as the percent of
patients with a claim for an osteoporosis agent at three, six, and
nine-months post-intervention. Additionally, a member survey
was conducted six-months post-intervention to evaluate the
member mailing. RESULTS: There were 1612 program partici-
pants. At three, six and nine-months respectively, 3.76%
(32/852), 5.12% (40/781) and 5.97% (42/704) of eligible
patients had a claim for an osteoporosis agent. A 23% survey
response rate was achieved (364/1612). Survey results indicated
18% of responders were taking prescription osteoporosis med-
ications at that time. Post-intervention, 19% of the responders
made a doctor appointment, 15% attended the appointment,
17% received a prescription, 13% received medication samples,
and 11% ﬁlled the prescription. CONCLUSION: Survey results
indicate higher rate of medication use compared to claims data-
base analysis, which does not capture medication sampling.
Another mailing has been done to continue to improve osteo-
porosis care.
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OBJECTIVE: Several features of bisphosphonate therapy for
osteoporosis may inﬂuence patient satisfaction, including dosing
convenience. The objective of this study was to evaluate the psy-
chometric characteristics of the Osteoporosis Patient Satisfaction
Questionnaire (OPSAT-Q), which assesses patient satisfaction
with osteoporosis treatment. METHODS: Patient focus groups
and cognitive debrieﬁngs informed the development of the 16-
item OPSAT-Q, which contains four subscales: Convenience,
Conﬁdence with Daily Activities, Side Effects and Overall Satis-
